Treatment with granulocyte colony-stimulating factor increases interleukin-1 receptor antagonist levels during engraftment following allogeneic stem-cell transplantation

European Journal of Clinical Investigation

Volumn 34, Issue 11, 2004, Pages 759-765

  Schwabe, M ^a   Hartert, A M ^a   Bertz, H ^a   Finke, Jürgen ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Allogeneic; Engraftment; G CSF; IL 1ra; Stem cell transplantation

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFECTION; LEUKOCYTE COUNT; NEUTROPENIA; PRIORITY JOURNAL;

BONE MARROW TRANSPLANTATION; C-REACTIVE PROTEIN; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA; LEUKOCYTE COUNT; NEUTROPENIA; POSTOPERATIVE PERIOD; RECEPTORS, INTERLEUKIN-1;

EID: 8744267075     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2004.01421.x     Document Type: Article

References (58)

1. Moore MAS. The clinical use of colony stimulating factors. Ann Rev Immunol 1991;9:159-83.
2. Morstyn G, Foote M, Perkins D, Vincent M. The clinical utility of granulocyte colony-stimulating factor: early achievement and future promise. Stem Cells 1994;12 (Suppl. 1):213-27.
3. Tabbara IA, Ghazal CD, Ghazal HH. The role of granulocyte colony-stimulating factor in hematopoietic stem cell transplantation. Cancer Invest 1997;15:353-7.
4. Stahel RA, Jost LM, Cerny T, Pichert G, Honegger H, Tobler A et al. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 1994;12:1931-8.
5. Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, Macdonald JS. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995;13:1323-7.
6. McQuaker IG, Hunter AE, Pacey S, Haynes AP, Iqbal A, Russell NH. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol 1997;15:451-7.
7. Schriber JR, Chao NJ, Long GD, Negrin RS, Tierney DK, Kusnierz-Glaz C et al. Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. Blood 1994;84:1680-4.
8. Lee SJ, Weller E, Alyea EP, Ritz J, Soiffer RJ. Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation. Blood 1998;92:2725-9.
9. Ringden O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004;22:416-23.
10. Nicola NA. Granulocyte colony-stimulating factor. Immunol Series 1990;49:77-109.
11. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991;78:2791-808.
12. Ohsaka A, Saionji K, Sato N, Mori T, Ishimoto K, Inamatsu T. Granulocyte colony-stimulating factor down-regulates the surface expression of the human leucocyte adhesion molecule-1 on human neutrophils in vitro and in vivo. Br J Haematol 1993;84:574-80.
13. Yuo A, Kitagawa S, Ohsaka A, Ohta M, Miyazono K, Okabe T et al. Recombinant human granulocyte colony-stimulating factor as an activator of human granulocytes: potentiation of responses triggered by receptor-mediated agonists and stimulation of C3bi receptor expression and adherence. Blood 1989;74:2144-9.
14. Kerst JM, van de Winkel JG, Evans AH, de Haas M, Slaper-Cortenbach IC, de Wit TP et al. Granulocyte colony-stimulating factor induces hFc gamma RI (CD64 antigen)-positive neutrophils via an effect on myeloid precursor cells. Blood 1993;81:1457-64.
15. Kerst JM, de Haas M, van de Schoot CE, Slaper-Cortenbach IC, von Kleijer M, von dem Borne AE et al. Recombinant granulocyte colony-stimulating factor administration to healthy volunteers: induction of immunophenotypically and functionally altered neutrophils via an effect on myeloid progenitor cells. Blood 1993;82:3265-72.
16. de Haas M, Kerst JM, van der Schoot CE, Calafat J, Hack CE, Nuijens JH et al. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. Blood 1994;84:3885-94.
17. Ohsaka A, Saionji K, Kuwaki T, Takeshima T, Igari J. Granulocyte colony-stimulating factor administration modulates the surface expression of effector cell molecules on human monocytes. Br J Haematol 1995;89:465-72.
18. Ohsaka A, Saionji K, Igari J. Granulocyte colony-stimulating factor administration increases serum concentrations of soluble selectins. Br J Haematol 1998;100:66-9.
19. Hartung T, Docke WD, Gantner F, Krieger G, Sauer A, Stevens P et al. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 1995;85:2482-9.
20. Pollmächer T, Korth C, Mullington J, Schreiber W, Sauer J, Vedder H et al. Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men. Blood 1996;87:900-5.
21. Pajkrt D, Manten A, vanderPoll T, Tiel-van Buul MMC, Jansen J, Wouterten CJ et al. Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans. Blood 1997;90:1415-24.
22. Rutella S, Rumi C, Testa U, Sica S, Teofili L, Martucci R et al. Inhibition of lymphocyte blastogenic response in healthy donors treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF): possible role of lactoferrin and interleukin-1 receptor antagonist. Bone Marrow Transplant 1997;20:355-64.
23. Lennard AC. Interleukin-1 receptor antagonist. Crit Rev Immunol 1995;15:77-105.
24. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998;16:27-55.
25. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1998;16:457-99.
26. Fisher CJ, Slotman GJ, Opal SM, Fribble JP, Bone RC, Emmanuel G et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. The IL-1ra Sepsis Syndrome Study Group. Crit Care Med 1994;22:12-21.
27. Bresnihan B, Cunnane G. Interleukin-1 receptor antagonist. Rheum Dis Clin North Am 1998;24:615-28.
28. Antin JH, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee SJ et al. Interleukin-1 blockade does not prevent acute graft versus host disease. Results of a randomized, double blind, placebo-controlled trial of interleukin 1 receptor antagonist in allogeneic bone marrow Transplantation. Blood 2002;100:3479-82.
29. Aman MJ, Keller U, Derigs G, Mohamadzadeh M, Huber C, Peschel C. Regulation of cytokine expression by interferon-α in human bone marrow stromal cell: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist. Blood 1994;84:4142-50.
30. Holmberg LA, Seidel K, Leisenring W, Torok-Storb B. Aplastic anemia: analysis of stromal cell function in long-term marrow cultures. Blood 1994;84:3685-90.
31. Chudgar UH, Rundus CH, Peterson VM. Recombinant human interleukin-1 receptor antagonist protects early myeloid progenitors in a murine model of cyclophosphamide-induced myelotoxicity. Blood 1995;85:2393-401.
32. Rimbaldi A, Torcia M, Bettoni S, Vannier E, Barbui T, Shaw AR et al. Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. Blood 1991;78:3248-53.
33. Estrov Z, Kurzrock R, Estey E, Wetzler M, Ferrajoli A, Harris D et al. Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood 1992;79:1838-945.
34. Bruserod O, Aasen I, Akselsen PE, Bergheim J, Rasmussen G, Nesthus I. Interleukin 1 receptor antagonsit (IL1RA) in acute leukemia: IL1RA is both secreted spontaneously by myelogenous leukaemia blasts and is part of the acute phase reaction in patients with chemotherapy-induced leucopenia. Eur J Haematol 1996;57:87-95.
35. Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris D et al. Suppression of chronic myeloid leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood 1991;78:1476-86.
36. Bertz H, Potthoff K, Mertelsmann R, Finke J. Busulfan/ cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity. Bone Marrow Transplant 1997;19:1169-73.
37. Berger C, Bertz H, Schmoor C, Behringer D, Potthoff K, Mertelsmann R et al. Influence of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donors. Bone Marrow Transplant 1999;23:983-90.
38. Bland JM, Altman DG. Calculating correlation coefficients with repeated observations: Part 1 - correlation within subjects. Br Med J 1995;310:446.
39. Bland JM, Altman DG. Calculating correlation coefficients with repeated observations: Part 2 - correlation between subjects. Br Med J 1995;310:633.
40. Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest 1997;99:2930-40.
41. Wetzler M, Kurzrock R, Estrov Z, Kantarjian H, Gisslinger H, Underbrink M et al. Altered levels of interleukin-1b and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood 1994;84:3142-7.
42. Re F, Mengozzi F, Muzio M, Dinarello CA, Mantovani A, Colotta F. Expression of interleukin-1 receptor antagonist (IL-1ra) by human circulating polymorphnuclear cells. Eur J Immunol 1993;23:570-3.
43. Malyak M, Smith MF, Abel AA, Arend WP. Peripheral blood neutrophil production of interleukin-1 receptor antagonist and interleukin-1 beta. J Clin Immunol 1994;14:20-30.
44. McColl SR, Paquin R, Menard C, Beaulieu AD. Human neutrophils produce high levels of the interleukin 1 receptor antagonist in response to granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha. J Exp Med 1992;176:593-8.
45. Schwaighofer H, Oberhuber G, Hebart H, Einsele H, Herold M, Nachbaur D et al. Endogenous interleukin 1 receptor antagonist during human bone marrow transplantation: increased levels during graft-versus-host disease, during infectious complications, and after immunoglobulin therapy. Transplantation 1997;63:52-66.
46. Liem LM, vanHouwelingen HC, Goulmy E. Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation 1998;66:863-71.
47. Hirsch E, Irikura VM, Paul SM, Hirsh D. Functions of interleukin 1 receptor antagonist in gene knock out and overproducing mice. Proc Natl Acad Sci USA 1996;93:11008-13.
48. Jovcic G, Ivanovic Z, Biljanovic-Paunovic L, Bugarski D, Stosic-Grujicic S, Milenkovic P. In vivo effects of interleukin-1 receptor antagonist on hematopoietic bone marrow progenitor cells in mice. Eur Cytokine Network 1996;7:71-4.
49. Neta R, Douches S, Oppenheim JJ. Interleukin-1 is a radioprotector. J Immunol 1986;136:2483-5.
50. Moore MA, Warren DJ. Synergy of interleukin-1 and granulocyte colony-stimulating factor, in vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice. Proc Natl Acad Sci 1987;84:7134-8.
51. Castelli MP, Black PL, Schneider M, Pennington R, Abe F, Talmadge JE. Protective, restorative, and therapeutic properties of recombinant human TT-1 in rodent models. J Immunol 1988;140:3830-7.
52. Atkinson K, Matias C, Guiffre A, Seymour R, Cooley M, Biggs J et al. In vivo administration of granulocyte colony-stimulating factor (G- CSF), granulocyte-macrophage CSF, interleukin-1 (IL-1), and IL-4, alone and in combination, after allogeneic murine hematopoietic stem cell transplantation. Blood 1991;77:1376-82.
53. Nemunaitis J, Appelbaum FR, Lilleby K, Buhles WC, Rosenfeld C, Zeigler ZR et al. Phase I study of recombinant interleukin-1 beta in patients undergoing autologous bone marrow transplant for acute myelogenous leukemia. Blood 1994;83:3473-9.
54. Weisdorf D, Katsanis E, Verfaillie C, Ramsay NK, Haake R, Garrison L et al. Interleukin-1 alpha administered after autologous transplantation: a phase I/II clinical trial. Blood 1994;84:2044-9.
55. Elkordy M, Crump M, Vredenburgh JJ, Petros WP, Hussein A, Rubin P et al. A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation. Bone Marrow Transplant 1997;19:315-22.
56. van Deuren M, van der Ven-Jongekrijg J, Vannier E, van Dalen R, Pesman G, Bartelink AKM et al. The pattern of interleukin-1β (IL-1β) and its modulating agent IL-1 receptor antagonist and IL-1 soluble receptor type II in acute meningococcal infections. Blood 1997;90:1101-8.
57. Granovitz EV, Santos AA, Poutsiaka D, Cannon JG, Wilmore DW, Wolff SM et al. Production of interleukin 1 receptor antagonist during experimental endotoxaemia. Lancet 1991;338:1423-6.
58. Weiss M, Moldawer LL, Schneider EM. Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis. Blood 1999;93:425-39.